Aim: To evaluate the phacoemulsification results of patients with primary angle closure (PAC) and primary angle closure glaucoma (PACG) using the Pentacam system. Method: This retrospective cohort study included patients with PAC and PACG who underwent phacoemulsification and intraocular lens implantation between 2018 and 2021 in one tertiary center. Anterior chamber parameters measured using the Pentacam system and gonioscopic and intraocular pressure (IOP) changes were evaluated preoperatively and postoperatively. Results: Nineteen eyes of 13 patients with PAC and PACG were included in the study. The mean age of the patients was 63.2 years, and 30.8% were male. The mean preoperative and postoperative third-month IOP was 21.0 ± 7.4 mmHg (11-40) and 13.7± 2.5 mmHg (9-18), respectively (p < 0.01). The mean preoperative anterior chamber angle (ACA) measured by the Pentacam system was 21.07 ± 4.16° (13-27). The mean preoperative anterior chamber depth (ACD) and the anterior chamber volume (ACV) measured by the Pentacam system were 1.79 ± 0.24 mm (1.39-2.22) and 72.55 ± 20.64 mm3 (45-109), respectively. The postoperative third-month topographic measurements were as follows: mean angle, 35.76 ± 7.32° (20.1-46.9); mean ACD, 3.52 ± 0.95 mm (1.15-4.46); and mean ACV, 133.21 ± 25.21 mm3 (81-173) (p < 0.01). Conclusion: Pentacam is a useful system to evaluate anterior segment changes after phacoemulsification in patients with PAC and PACG. Phacoemulsification was found to result in significant IOP reduction in these patients.
Hyperbaric oxygen therapy (HBOT) is a treatment modality commonly used for various medical conditions, such as diabetic foot ulcers and sudden hearing loss. This study aims to evaluate HBOT's effects on central corneal thickness (CCT) and other corneal topographic parameters through comprehensive ophthalmic assessment. Detailed ophthalmologic examinations and corneal topography measurements were performed on 92 patients with various non-ophthalmologic diseases, both before and immediately after undergoing HBOT. Corneal topography was measured before and after the therapy. The recorded parameters included central corneal thickness, anterior chamber depth, anterior chamber volume, and corneal volume. The patients were also categorised into two groups: diabetic (n = 22) and non-diabetic (n = 70). Following treatment, statistically significant reductions were observed in CCT (529.69 ± 31.7 μm vs. 526.63 ± 33 μm, p = 0.002) and corneal volume (58.63 ± 3.71 mm³ vs. 58.21 ± 3.58 mm³, p = 0.016). Conversely, anterior chamber volume significantly increased (124.38 ± 30 mm³ vs. 126.42 ± 30.7 mm³, p = 0.003). Comparative analysis between diabetic and non-diabetic groups revealed no substantial differences in CCT and corneal volume changes following HBOT. However, the diabetic group exhibited significantly lower baseline anterior chamber volume before treatment (p = 0.01 and p = 0.042). HBOT administration resulted in measurable reductions in CCT and corneal volume, along with an increase in anterior chamber volume, in all treated eyes. The observed decrease in corneal thickness manifested less prominently in diabetic patients compared to their non-diabetic counterparts, suggesting potential metabolic influences on corneal response to hyperoxic conditions.
1 January 2024 in Revista da Associação Médica Brasileira
The aim of this study was to evaluate the choroidal thickness and choroidal vascular index in normotensive individuals with dipping and nondipping patterns.
The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52 weeks of follow-up. Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit. A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54 weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3 µm (from 594.1 ± 206.9 µm at baseline to 287.2 ± 89.9 µm at final visit; p < 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3 µm (from 562.1 ± 107.3 to 271.5 ± 90.7 µm; p < 0.001). The mean logMAR BCVA gain was 0.77 (p < 0.001) in naïve and 0.38 (p < 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded. Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.
1 January 2026 in Case Reports in Ophthalmological Medicine
Introduction: To report an unusual epiretinal proliferation (EP) case in tubercular serpiginous–like choroiditis. Case Presentation: A 30‐year‐old female patient with a history of uveitis presented with blurry vision and floaters for 5 days. The visual acuities of the right and left eyes were 7/10 and 9/10, respectively. A slit lamp examination of the right eye showed moderate anterior uveitis with anterior chamber cells of 2+ and 1+ cells in the anterior vitreous. The left eye showed a posterior synechia at the inferior half of the pupil but no cells in the anterior chamber. Mild vitritis was observed in both eyes. A fundus examination revealed two atrophic punch‐out lesions in the right eye and multiple pigmented chorioretinal scar–like lesions in the left eye. OCT showed cystoid macular edema in the right eye and a wide epiretinal proliferative membrane in the left eye. The immunocompetent patient had a family history of tuberculosis (TB) infection. The tuberculin skin test resulted in a ≥ 20‐mm induration, and the QuantiFERON‐TB Gold test was positive. The patient was started on topical and oral steroids. Additionally, anti‐TB treatment was added, leading to a favorable outcome. Following treatment, signs of panuveitis showed resolution, and there was an improvement in vision symptoms. Conclusions: To our knowledge, this may represent one of the first reported cases of EP associated with tubercular serpiginous–like choroiditis.
15 September 2025 in Romanian Journal of Ophthalmology
Ampiginous choroiditis is a disease that includes features of both acute posterior multifocal placoid pigment epitheliopathy and serpiginous choroiditis. This article presents two patients who were diagnosed with ampiginous choroiditis in our clinic. A 28-year-old female patient presented to our clinic with blurred vision that had persisted for 2 weeks. Her best corrected visual acuity (BCVA) was 20/20. Her medical history included a COVID-19 infection about 1 month before. Fundoscopic examination revealed multiple grayish-yellow lesions with irregular borders and pseudopodial extensions, involving the posterior poles of both eyes diffusely. Fundus findings and multimodal imaging, including optical coherence tomography, fundus autofluorescence imaging, and fundus fluorescein angiography, indicated ampiginous choroiditis. The patient was treated with oral steroids and azathioprine. The second patient was a 34-year-old male under follow-up in the neurology clinic, with a diagnosis of transverse myelitis, who was referred to us for an ophthalmologic consultation. The patient had a COVID-19 infection a few weeks prior. The patient had no visual symptoms in our first examination, and his BCVA was 20/20. Fundus examination and multimodal imaging were associated with ampiginous choroiditis. The patient’s ongoing treatment was initiated by neurology, including oral steroids and azathioprine therapy. This treatment regimen was continued, and follow-up was conducted. In conclusion, these two cases suggest that the SARS-CoV-2 virus may serve as an immunogenic trigger for the development or reactivation of ocular inflammatory diseases in individuals predisposed to white dot syndromes.